Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. - Wikidata - awgldk - TriplyDB

Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products.

Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products.

http://www.wikidata.org/entity/Q42414162

about

RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis New insights into the regulation of neutrophil NADPH oxidase activity in the phagosome: a focus on the role of lipid and Ca(2+) signaling S100A8 and S100A9 in cardiovascular biology and disease Revisiting the adipocyte: a model for integration of cytokine signaling in the regulation of energy metabolism S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4 S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy S100A1: a multifaceted therapeutic target in cardiovascular disease Calprotectin--a novel marker of obesity.Proinflammatory effects of S100A8/A9 via TLR4 and RAGE signaling pathways in BV-2 microglial cells S100A8 and S100A9 in experimental osteoarthritis.ANTI-INFECTIVE PROTECTIVE PROPERTIES OF S100 CALGRANULINS.-374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease.S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation.Injury-induced MRP8/MRP14 stimulates IP-10/CXCL10 in monocytes/macrophages Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients.Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins Functional characterization of S100A8 and S100A9 in altering monolayer permeability of human umbilical endothelial cells S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo.Chronic alcohol administration causes expression of calprotectin and RAGE altering the distribution of zinc ions in mouse testis.Post-ICU discharge and outcome: rationale and methods of the The French and euRopean Outcome reGistry in Intensive Care Units (FROG-ICU) observational study.S100A11, an dual mediator for growth regulation of human keratinocytes MRP8/14 enhances corneal susceptibility to Pseudomonas aeruginosa Infection by amplifying inflammatory responses.Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA expression in newly diagnosed diabetes subclinical vascular lesions.Review of S100A9 biology and its role in cancer.Functions of S100 proteins.The expression of inflammatory genes is upregulated in peripheral blood of patients with type 1 diabetes Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs.Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.Catalpol ameliorates diabetic atherosclerosis in diabetic rabbits.S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease.Inflammation-associated S100 proteins: new mechanisms that regulate function.Dietary hyperglycemia, glycemic index and metabolic retinal diseases.RAGE biology, atherosclerosis and diabetes.Novel insights into the role of S100A8/A9 in skin biology.Fecal calprotectin in pediatric inflammatory bowel disease: a systematic review.RAGE regulation and signaling in inflammation and beyond.Adipokines and their receptors: potential new targets in cardiovascular diseases.S100-alarmins: potential therapeutic targets for arthritis.Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor.

P2860

Q24658378-C582A58D-6448-4EC9-88A0-D6E3069DA36C Q27004060-F75CE3A6-E8A1-40BE-8058-7AAC43FA8371 Q27024450-993AD4EC-DA45-4BE0-BD39-6ED73392798D Q28085224-6EF47ECC-62E6-4BF6-8EB6-7E18F4DF4CEA Q28240188-CBE88FFD-021E-4588-95FF-596E2DAE7840 Q28249115-AB537D35-CC7F-45F8-8B7F-06E99290DB98 Q28288362-A4FC5686-50C2-4DC7-B4E6-D2EC625DFB77 Q33510158-9F9C0E42-4B0B-4D57-936B-0F68015BC259 Q33783947-E59E7499-EEFC-4CCA-A995-EC52C15268A6 Q33873682-1DB60C25-EB9D-48EF-B4DB-C91C711A24F2 Q33890061-EC596D62-5656-4593-B4E6-E1D2E90C242C Q34672674-8113F7B3-9A10-4610-BC5F-9611271A165E Q34769986-65288C09-E550-46D6-A183-10638B61B949 Q34847755-927C5A20-0A51-4469-9E3F-BAD3F267410E Q35061053-45CD1CDB-423E-4506-BC95-3C37B9E44DAF Q35063189-C1BCA5EA-44A5-4D58-A669-961C600C540B Q35111301-C9F4F760-23AB-49DF-93AD-96C360FC3D22 Q35112587-84D114C3-945B-4495-964C-98D603381343 Q35228472-44FC1F64-7000-4D62-95F5-C5AC3CCF30D1 Q35804116-AFC8307A-9926-4816-8B3E-B66A4AD9D0EF Q36325990-3BE611A6-8C61-44CA-8EE1-ECF93BEF09B5 Q36617801-93F35055-7F78-407B-8668-88AB41CB6E8F Q36865137-CE8C24AD-B0F8-4FA5-9193-AB26ACF5951B Q36896567-D2B47AF9-95FF-495B-A5D7-2F4295BA470B Q37001259-D9EB8AC7-80F4-4C18-9787-3FFA8D7EAE76 Q37106490-058D0F0A-8FC7-4954-A785-3A5F89E08448 Q37120232-FC59300E-00B8-450A-B6C6-A52478E3F9BA Q37206919-79EABC96-F380-4CD7-97E7-6FDD7B5456DA Q37229916-D87844DC-FE73-4D14-B20B-730229DF6130 Q37393435-9F0AC0EF-4706-4624-9266-3DB5B71672C8 Q37436729-21012CFD-7D00-423C-9735-021115CEF907 Q37705110-B7DEA3F0-26A4-45B2-A6B9-D5F691794694 Q37733102-2D042C49-A522-41F3-8F26-EA5461ED55F1 Q37860348-9900D897-065F-42DE-BE07-B94AAF79B0C3 Q38033682-F33AEC8A-C497-4712-AB05-2946355CDF9E Q38035199-380CB8C6-5417-4418-9338-855048D36E7D Q38094691-593359A6-D9BC-412E-A310-90566BAFBB57 Q38357078-BB7C4BA8-5DBE-4E77-9E4A-2AD48A5371A8 Q38685009-8719D07A-4555-4BD4-8DD4-97B583CC87E1 Q38685706-6D1C631B-DB01-4378-AA7D-AA2162F0B72E

P2860

Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products.

http://www.wikidata.org/entity/Q42414162

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Increased proinflammatory endo ...... vanced glycation end products.

@en

Increased proinflammatory endo ...... vanced glycation end products.

@nl

type

label

Increased proinflammatory endo ...... vanced glycation end products.

@en

Increased proinflammatory endo ...... vanced glycation end products.

@nl

prefLabel

Increased proinflammatory endo ...... vanced glycation end products.

@en

Increased proinflammatory endo ...... vanced glycation end products.

@nl

P1433

Q42414162-50DAE056-9F92-4C2D-9766-515BA4D9ED9A

P1476

Q42414162-16A492B3-406D-4B82-838B-71804A5183B8

P2093

Q42414162-0278B03D-9A94-489D-B4B4-C898A5ACEAC9

Q42414162-5277A8C7-D17E-4D9B-A76C-F69D3D253162

Q42414162-5B95E9DC-85F9-46FB-B728-24CA9E6D27FC

Q42414162-6FE0F511-B092-477F-8F4D-F823C4381F46

Q42414162-7906E957-4BA3-4A0D-860C-8199741A5C9C

Q42414162-890137A9-CA47-407E-9BE5-0E6CD28E7D2E

Q42414162-9BA593ED-0755-45C0-A32D-27F503C35F83

Q42414162-B8462A0D-070C-4384-99C7-45753E10711A

P2860

Q42414162-031C7E31-161A-404A-AD2D-6EADDB38A858

Q42414162-03C83A49-56C6-449A-9E55-5F469DA8EF2E

Q42414162-0D2FD06B-2346-4A53-9A38-CB67AE4F8F4D

Q42414162-1A70D18D-FCF1-4F34-A7EE-062A892D1E5F

Q42414162-1DE7EB70-6324-4CC2-820E-A2A5CBA89C18

Q42414162-25050D33-6503-4872-9256-6B1DE0EDFEA3

Q42414162-39FE624D-C2CD-494B-B6B3-A6DA9A1C1BA4

Q42414162-3DF588B2-2104-43B5-A755-EA316F709739

Q42414162-4B109787-903E-4B97-99C9-0109BC3FCED2

Q42414162-585E648D-08A4-4150-8423-E82314F71B23

P2888

Q42414162-AC58A7CB-88EA-49F7-B219-EC5BA684B745

P304

Q42414162-D0197C44-7F2D-4D1E-9827-7808CB74F8B2

P31

Q42414162-313A0B6F-C245-444A-BDE9-2746F18AC7F9

P356

Q42414162-F5C545C5-A018-452C-839B-39A10E1314C5

P407

Q42414162-AE56585F-FC09-4425-B594-C88865DD76F2

P478

Q42414162-127E340A-8F98-4E20-82A7-8EBC89A190B1

P50

Q42414162-C6D2856E-AE91-4049-9F32-FD8046751A18

P577

Q42414162-34C58019-11A6-4BF7-8140-C958EFCF6179

P5875

Q42414162-DF812A06-95BB-4546-B17F-EDA29E8556D1

P6179

Q42414162-585CECE4-24C4-440E-899F-42474ECDC6D1

P698

Q42414162-ADC699ED-1A70-4F4E-98EA-728746323AC9

P921

Q42414162-8CDA4D6A-F1E2-4A8A-AF9D-2654A887ADD6

P932

Q42414162-283C3C89-333C-46F2-949E-7CE803A122A9

P356

P1433

Cardiovascular Diabetology

P1476

Increased proinflammatory endo ...... vanced glycation end products.

@en

P2093

Andrew Remppis

http://www.w3.org/2001/XMLSchema#string

Angelika Bierhaus

http://www.w3.org/2001/XMLSchema#string

Dieter Weichenhan

http://www.w3.org/2001/XMLSchema#string

Hugo A Katus

http://www.w3.org/2001/XMLSchema#string

Kai Eggers

http://www.w3.org/2001/XMLSchema#string

Patrick Most

http://www.w3.org/2001/XMLSchema#string

Peter P Nawroth

http://www.w3.org/2001/XMLSchema#string

Philipp Ehlermann

http://www.w3.org/2001/XMLSchema#string

P2860

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation

Atherosclerosis — An Inflammatory Disease

Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells

Intracellular and extracellular roles of S100 proteins

Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB

The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils

The S100 family of EF-hand calcium-binding proteins: functions and pathology

Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9)

A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene

P2888

P304

6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1475-2840-5-6

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Johannes Greten

P577

2006-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7205366

http://www.w3.org/2001/XMLSchema#string

P6179

1010442301

http://www.w3.org/2001/XMLSchema#string

P698

16573830

http://www.w3.org/2001/XMLSchema#string

P921

P932

1475836

http://www.w3.org/2001/XMLSchema#string